CICC Capital led the investment, and the assisted reproduction enterprise "Ruifuda Medical" completed a Series B financing of tens of millions of yuan.
36Kr has learned that Jiangsu Ruifuda Medical Devices Co., Ltd. (hereinafter referred to as "Ruifuda Medical") recently completed a Series B financing of tens of millions of yuan.
This round of financing was led by a fund managed by CICC Capital, with the industrial fund of Lianyungang Economic and Technological Development Zone participating as a follow - on investor. The raised funds will be mainly used for the technological R & D of the company's core products, the exploration of domestic and overseas markets, the upgrade of production capacity, and the team building.
In recent years, the policy support for assisted reproductive technology has been continuously increasing. At the beginning of this year, the National Healthcare Security Administration disclosed that since 31 provincial - level administrative regions and the Xinjiang Production and Construction Corps in China have successively included assisted reproductive technology in the medical insurance, it has benefited more than one million people. At the social level, the three - child policy has been fully liberalized, and continuous capital investment has also heated up this sector, giving rise to many medical device and consumable companies as well as medical service providers.
Riding on the wave of this sector, Ruifuda Medical was officially established in 2018, focusing on the R & D of consumables and reagents in the field of assisted reproduction. The founder, Fu Yang, once worked at CooperSurgical and has over 20 years of work experience in the assisted reproduction industry, having fully participated in the whole process from laboratory product R & D to industrialization. Currently, Ruifuda Medical's product pipeline covers the cryopreservation, embryo culture, and in - vitro fertilization processes of in - vitro fertilization (IVF) technology.
In March this year, a core patented product of Ruifuda Medical, the closed cryopreservation carrier rod for the vitrification freezing technology of assisted reproductive embryos, was officially approved for marketing. So - called vitrification freezing is like "pausing" time. It refers to a process where embryos are treated through a series of steps to form a non - crystalline vitrified state in an ultra - low - temperature environment, thereby reducing freezing damage and extending the preservation period. Currently, although this technology is widely used in the field of assisted reproduction, it is relatively dependent on imports.
It is reported that the closed cryopreservation carrier rod product approved by Ruifuda Medical this time mainly solves two key problems in vitrification freezing: "rapid cooling" and "closed anti - pollution". First, the product uses a unique liquid refrigerant design, which can achieve the same freezing and cooling rate as an open carrier rod. At the same time, the closed carrier rod can effectively isolate the direct contact between the sample and liquid nitrogen, thereby reducing the risk of cross - infection between embryos of different patients and the potential microbial infection risk in liquid nitrogen storage.
Schematic diagram of Ruifuda Medical's "closed cryopreservation carrier rod"
In addition, as product R & D matures, Ruifuda Medical's market promotion is also advancing step by step. In April this year, the self - developed vitrification freezing solution and thawing solution set of the company was approved by the US FDA. The company said that while accelerating the implementation of products in the domestic market and expanding production capacity, it will "vigorously explore the international market".
It is also learned that as of now, Ruifuda Medical has filed a total of 6 invention patents and was successfully recognized as a national high - tech enterprise in March 2025.
Views of investors and the company:
CICC Capital said that Ruifuda Medical has demonstrated strong R & D capabilities and efficient industrialization capabilities in the niche field of assisted reproduction and is a leader among domestic medical device companies. We look forward to supporting the company through this round of investment to build stronger technological barriers and broader market prospects under the dual drive of domestic substitution and international expansion.
The person in charge of investment promotion at Lianyungang China Pharmaceutical Port said that as a representative enterprise in the medical device sector of Lianyungang China Pharmaceutical Port, Ruifuda has strong development potential and momentum. We firmly support the development of the enterprise, give full play to the guiding effect of the industrial fund, and gather more resources to help Ruifuda stay at the forefront in the field of assisted reproduction.
Ruifuda Medical said that this Series B financing is a key milestone in the company's development and also marks an important step for domestic assisted reproduction devices to reach higher standards. Taking this as an opportunity, the company will continue to promote technological innovation, strengthen quality control, improve service capabilities, and accelerate the wide application of core products globally.